安罗替尼三线及以上治疗老年晚期肺癌患者的疗效及安全性分析

Analysis of the Efficacy and Safety of Anlotinib Third-line and Above in the Treatment of Elderly Patients with Advanced Lung Cancer

目的探讨安罗替尼三线及以上治疗老年晚期肺癌患者的疗效及安全性。方法方便选取回顾性分析2018年1月—2019年6月该院收治的43例至少二线及以上治疗失败的、接受安罗替尼治疗的老年晚期肺癌患者,按照实体瘤疗效评价标准(RECIST 1.1)评价疗效,常见不良事件评价标准(CTCAE 4.02)评价药物不良反应。结果安罗替尼治疗的客观缓解率为13.95%(6/43),疾病控制率为81.40%(35/43);疗效评价结果显示:CR 0例(0.00%),PR 6例(13.95%),SD 29例(67.44%),PD 8例(18.60%);ORR为13.95%(6/43),DCR为81.40%(35/43);最常见不良反应中1~2级较多,高血压、乏力、食欲减退、手足综合征、甲状腺功能异常、转氨酶升高、腹泻、蛋白尿等占比分别为65.12%、60.47%、53.49%、41.86%、37.21%、34.88%、30.23%、25.58%,3~4级不良反应较少。结论安罗替尼在老年晚期肺癌患者三线及三线以上治疗中疾病控制较好,总体耐受性和安全性可控,是老年晚期肺癌患者多线治疗失败后的可选药物。

Objective To explore the efficacy and safety of anlotinib third-line and above in the treatment of elderly patients with advanced lung cancer.Methods Conveniently select from January 2018 to June 2019,43 elderly patients with advanced lung cancer who had failed at least second-line and above treatment and received anlotinib treatment were enrolled in the hospital from January 2018 to June 2019.The efficacy was evaluated according to the efficacy evaluation criteria for solid tumors(RECIST 1.1).Common Adverse Events Evaluation Criteria(CTCAE 4.02)evaluates adverse drug reactions.Results The objective response rate of Anlotinib treatment was 13.95%(6/43),and the disease control rate was 81.40%(35/43).The results of the efficacy evaluation showed:CR 0 cases,PR 6 cases(13.95%),SD 29 cases(67.44%),8 cases of PD(18.60%);ORR was 13.95%(6/43),DCR was 81.40%(35/43);the most common adverse reactions were grade 1-2,high blood pressure and fatigue,loss of appetite,hand-foot syndrome,abnormal thyroid function,elevated transaminase,diarrhea,proteinuria,etc.accounted for 65.12%,60.47%,53.49%,41.86%,37.21%,34.88%,30.23%,25.58%,3-4 degree of adverse reactions.Conclusion Anlotinib has good disease control in the third-line and above treatment of elderly patients with advanced lung cancer,and its overall tolerability and safety are controllable.It is the drug of choice for elderly patients with advanced lung cancer after failure of multi-line therapy.